Biosyent Inc (TSE:RX) has released an update.
BioSyent Inc. has announced robust financial results for Q4 and the full year of 2023, showcasing a significant growth in Canadian pharmaceutical sales by 10% and an overall company sales increase of 13%. The company has strengthened shareholder value through regular dividends and share buybacks, while maintaining a net profit margin of 20%. This performance is attributed to the successful launch of new products and the strategic focus on long-term growth and portfolio diversification.
For further insights into TSE:RX stock, check out TipRanks’ Stock Analysis page.
